

NEUROENDOCRINE CANCER: AN OVERVIEW FOR GASTROENTEROLOGISTS

KEY POINTS

- **Neuroendocrine cancers, often referred to as neuroendocrine neoplasms (NENs), are now the second most prevalent GI cancers and the 10th most prevalent cancers in England.(1)**
- **There are challenges to diagnosing NENs** because individual symptoms may mimic or be masked by more common conditions such as IBS. This can also be exacerbated by a perceived pressure to discharge patients with these symptoms who have had a normal gastroscopy and/or colonoscopy.(2)
- **Many gastrointestinal NEN patients are initially misdiagnosed and treated for the wrong disease.**
- **CT and/or MR imaging can assist in detecting NENs in symptomatic patients where a diagnosis has not been established by endoscopic or other means.** Clinical features that may suggest a need for further investigations such as contrast-enhanced abdominal CT scan may include persistent symptoms (e.g. diarrhoea or abdominal pain), new onset of symptoms in older patients in whom a new diagnosis of IBS is less likely, the presence of one or more carcinoid syndrome symptoms (facial flushing, diarrhoea, bronchospasm), weight loss or bowel obstructive symptoms.(2)
- **The diagnosis of a Neuroendocrine Cancer can result in a significant and negative impact on the quality of life for patients** (and their families). This is due to multiple factors including the impact of a new cancer diagnosis, potential tumour-associated hormonal symptoms, information, and diagnostic barriers and delays, alongside an often incurable and uncertain prognosis.(3)
- **Diagnosing patients earlier is life-changing because there are treatments that can improve the prognosis as well as symptoms even in the presence of metastatic disease.**

DEFINITION OF NEUROENDOCRINE CANCER

Neuroendocrine neoplasms (NENs) are a heterogeneous group of cancers, which arise in the neuroendocrine cells. The WHO has defined two principal subtypes – neuroendocrine tumours (NETs) and neuroendocrine carcinomas (NECs):

Neuroendocrine Tumours (NETs) and Neuroendocrine Carcinomas (NECs).
Both subtypes are considered as malignant tumours.

Neuroendocrine tumours (NETs)	Neuroendocrine carcinomas (NECs)
<ul style="list-style-type: none"> • Two-thirds of NENs are NETs ~70% • Well-differentiated • Slow to rapid growth - Graded 1-3 • Relatively good prognosis • May present/develop site-associated hormone syndrome 	<ul style="list-style-type: none"> • One-third of NENs are NECs ~30% • Poorly differentiated • Rapid growth - Grade 3 • Poor prognosis • May present/develop paraneoplastic syndrome

The likely locations of Neuroendocrine neoplasms (5)


Lung / Bronchus: 20-30%

Digestive System: 60%

Stomach: 5%
Pancreas: 10%
Small Intestine: 5-25%
Colon: 13%
Rectum: 10-25%

Other Locations: 15%

Skin
Thymus
Ovary
...




NENs are complex with aspects of both a cancer and a chronic disease and may develop almost anywhere in the body, most commonly within the respiratory or digestive tracts (GI tract /pancreas).


- Neuroendocrine neoplasms arising from the digestive tract are referred to as gastro-entero-pancreatic NENs (GEP-NENs), and these account for over 60% of NENs(4).
- The respiratory system represents the site of disease in 20-30% of patients, and less commonly affected sites include skin, thymus, and reproductive system structures, such as the ovaries.

Determining whether patients have NETs or NECs is of vital importance, as this can have a significant impact on prognosis as well as treatment planning.(6) There are significant differences in 5-year survival of NETs and NECs.(7)

(A) Neuroendocrine tumours



(B) Neuroendocrine carcinoma



NENs are not as rare as you may think

“Most gastroenterologists will intermittently diagnose new cases of NET and, in addition, they are likely to regularly encounter patients who have established NET diagnoses.”(2)

- Between 1995-2018 the incidence of NENs has risen 371%: age-adjusted incidence increases from 2.35 to 8.61 per 100,000.(1)
- Neuroendocrine neoplasms have a higher prevalence than incidence: incidence ~ 9 per 100,000(1), prevalence ~ 35 per 100,000.(8)

CLINICAL PRESENTATION

- **Diagnosing NENs is challenging with data and patient experience reports indicating an average time to diagnosis of 3 years.(2)**
 - Symptoms may mimic or be masked by more common conditions such as IBS, Asthma or Menopause.(9)
 - **Routine tests may not raise suspicion or diagnosis of NENs, e.g. small bowel NENs may have negative endoscopy and normal FBC and CEA, despite bowel symptoms.**
 - Symptoms may be tumour and/or hormone excess related. However, many may be asymptomatic at early stages, found incidentally through screening or other tests.
- Those with functioning tumours can have specific symptoms for example, those with carcinoid syndrome may present with the classical triad of diarrhoea, flushing and/or wheeze.
- More than 50% of all cases, will have Stage III-IV disease at the time of diagnosis.(10)
- In contrast to most other GI cancers, some patients who have widespread stage 4 NETs have a relatively good prognosis, especially when the tumour is grade 1.

THINGS TO LOOK OUT FOR THAT COULD BE INDICATIVE OF NEUROENDOCRINE NEOPLASMS

- Peptic Ulcers (especially if unusual in size or number) in patients with no obvious cause such as H. pylori infection or aspirin/NSAID use and/or with an incomplete response to standard doses of PPIs.
- Continuing abdominal pain
- Small amounts of weight loss
- Minimal response to routine medications such as loperamide or antispasmodics
- Symptoms similar to those caused by any tumour at a particular anatomical site (e.g. small bowel obstruction)
- General symptoms associated with a metastatic tumour (e.g. weight loss, fatigue).

USEFUL INVESTIGATIONS FOR DIAGNOSING NEUROENDOCRINE NEOPLASMS

- For people with persistent, troublesome, particularly watery diarrhoea for whom the standard tests have not confirmed a diagnosis, consider a functional NET and arrange a Gut Hormone Profile and measurement of plasma/urinary 5-HIAA.⁽¹¹⁾
- Chromogranin A is the most useful general biomarker for NENs but is not completely sensitive or specific. It is helpful for patients with confirmed NEN but shouldn't be used as a screening test.
- Unusual-looking polyps in the stomach, duodenum, or rectum that could potentially be NENs should initially be biopsied rather than being removed at the time of the initial endoscopy. If a NEN is histologically confirmed, full tumour characterisation and staging is required to determine the optimal treatment plan.
- CT and MR imaging are useful for patients with persistent abdominal pain and diarrhoea and will often detect previously undiagnosed NENs. However, they will not necessarily demonstrate the full extent of disease.
- Nuclear medicine scans (e.g. Ga DOTATATE PET/CT and FDG-PET/CT), whilst not available in every hospital, can be very useful for determining the full extent of the disease and the optimal treatment plan and these should be considered before proceeding to treatment unless it is an emergency.
- Refer patients with a confirmed or highly suspected diagnosis of NET/NEC on to your local NET MDT or Centre of Excellence.

Spotlight on Neuroendocrine Cancer is a collaboration between UKINETS & NCUK



UK & Ireland Neuroendocrine
Tumour Society
www.ukinets.org



Clinical guidelines are available - alongside expert advice from any one of 14 UK accredited European Centres for Neuroendocrine Cancer - should NENs be suspected/diagnosed: UKINETS: www.ukinets.org ENETS: www.enets.org

Patient-facing & HCP information, education and support is available from Neuroendocrine Cancer UK
www.neuroendocrinecancer.org.uk
Office: 01926 883487 | Helpline: 0800 434 6476
www.neuroendocrinecancer.org.uk



The lack of a national pathway and non-inclusion in NG12 differentials has hampered the diagnosis of NENs, however, a collaborative multistakeholder working group – including NHS Early Diagnostic leads – has addressed this disparity. The Neuroendocrine Cancer Patient Care Pathway will launch May 2023. Visit www.neuroendocrinecancer.org.uk for further information and updates.

References

1. White et al. 2022;23: 100510 The Lancet Regional Health – Europe. Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population- based study
2. Khan MS, Pritchard DM. Frontline Gastroenterology 2022; 13:50-56. Neuroendocrine tumours: what gastroenterologists need to know.
3. Winter K, Bouvier C Open Conversations: Neuroendocrine Cancer and Mental Health Report, rareminds charity and Neuroendocrine Cancer UK
4. Das, S & Dasari, A, Curr Oncol Rep. 2021 Mar 14;23(4):43Epidemiology, Incidence and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
5. Cuny et al. Endocrine-Related Cancer 25, 11; Role of the tumor microenvironment in digestive neuroendocrine tumors 10.1530/ERC-18-0025
6. J Eads: Assistant Professor of Medicine, University Hospitals Cleveland Medical Centre
7. Kaplan–Meier predicted 5–year survival of (A) 11,080 neuroendocrine tumours and (B) 3,754 neuroendocrine carcinomas between 2012 and 2018 in England. Source data: NCRAS.
8. Yao JC et al. J Clin Oncol. (2008); 26(18):3063-3072
9. Basuroy et al. BMC Cancer 2018;18(1):1122. Delays and routes to diagnosis of neuroendocrine tumours.
10. Genus et al. British Journal of Cancer, 2019 Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013-2013.
11. More details in the BSG Guidelines for the investigation of chronic diarrhoea.